Health Business Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Affitech As

Affitech Acquires Pharmexa's Diabody Technology

announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company. Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties.

...

• View Other Issues of Health Business Week
  
• View Other NewsRx Publications